What Is Human Recombinant Erythropoietin?

Recombinant human erythropoietin- is suitable for dialysis patients with anemia caused by chronic renal failure.

Recombinant human erythropoietin-

This entry lacks an overview map . Supplementing related content makes the entry more complete and can be upgraded quickly. Come on!

Recombinant human erythropoietin- is suitable for dialysis patients with anemia caused by chronic renal failure.

Drug Name

Recombinant human erythropoietin-

Alias

Rocoman

Foreign name

Recombinant human erythropoietin beta

Main indications

Dialysis patients due to chronic kidney failure

Dosage

Intravenous, subcutaneous

Adverse reactions

Alias

Rocoman, Recombinant Human Erythropoietin-, Recombinant Human Erythropoietin-, Beta Epoetin, Hematopoietin

Foreign name

Recombinant human erythropoietin beta, Recormon

The lyophilized powder can be injected subcutaneously or intravenously after dissolution.

Dose (each and every week)

The treatment goal is to increase the hematocrit between 30-35%, with an average weekly increase of at least 0.5%, and the highest level cannot exceed 35%. If there is hypertension or cardiovascular disease, cerebrovascular or terminal vascular disease, etc., the weekly increase and target level should be determined according to individual conditions. For some patients, the ideal level may be below 30%.

There are two steps to the hematopoietic treatment plan:

a. Treatment period:

Subcutaneous injection: The initial treatment dose is 3 × 20IU / kg body weight per week. If it is found that the increase in hematocrit is unsatisfactory (less than 0.5 vol% per week), the dose can be increased by 33 × 20 IU / kg body weight / week after 4 weeks. The weekly dose can also be divided into daily doses.

Intravenous injection: The initial treatment dose is 33 × 40IU / kg body weight per week. If it is found that the increase of blood cells is not satisfactory (less than 0.5vol% per week), the dose can be increased to 3 × 80IU / kg body weight / week after 4 weeks. After that, it can increase by 3 × 20IU / kg body weight per week per week.

For the above two routes of administration, the highest dose should not exceed 720IU / kg body weight per week.

b. Maintenance period:

To maintain a hematocrit between 30 vol% and 35 vol%, first reduce the dose to half of the treatment period, and then adjust the dose weekly or biweekly.

Clinical observations on children show that, on average, the younger the patient, the higher the maintenance dose of hematopoietic hormone. However, due to the different responses of individual patients, it is difficult to estimate, so the drug should be applied at the recommended dosage.

Hemolysin is generally used for long-term treatment, but it can be terminated at any time if necessary.

Usage

Hematopoiesis should be used under the careful monitoring and guidance of medical personnel.

Since cases of allergic reactions have been found, it is recommended that the first administration should be performed under the supervision of medical personnel.

Heparin is supplied as lyophilized powder in vials.

When used, dissolve hematogen in the accompanying solvent, but use it immediately (within 2 hours).

Before use, make sure that the solution should be colorless and particulate-free, transparent or slightly milky before use. Discard leftover medication.

This medicine solution can be used for subcutaneous injection or intravenous injection.

Intravenous injection should be completed in about 2 minutes. For example, it is injected through an arteriovenous fistula at the end of the dialysis procedure. Non-dialysis patients should be injected subcutaneously to avoid puncturing the peripheral veins.

Taboo for important cooperation

Pay attention to the following tips to avoid causing mismatches or affecting activity;

-Do not use other solvents!

-Never mix with other drugs!

-Do not use glass injection devices, use plastic products!

Cardiovascular system: The most common adverse reactions during treatment are increased blood pressure or worsened hypertension, which can be treated with appropriate drugs. If blood pressure cannot be controlled with drugs, hematopoietic hormones must be temporarily stopped. Blood pressure should be monitored at regular intervals, and monitoring should also be carried out between each analysis (especially at the beginning of treatment).

Hypertensive crises with encephalopathy-like symptoms (such as headaches, confusion, sensory and / or motor disorders such as talking disorders, gait disorders, and clonic episodes, etc.) may occur in patients with normal or hypotension Occurrence. Such patients should be closely monitored immediately, especially those with acute acupuncture migraine.

Blood: Heparin may cause

Rokman is contraindicated in patients with uncontrolled hypertension.

Although animal tests have not shown that hematopoiesis can cause teratogenicity, the use of hematopoiesis is not recommended during pregnancy and lactation, as current clinical experience in this area is still insufficient.

If used incorrectly by normal people (for example, as a stimulant), it can cause excessive cell specific volume, which can cause various fatal cardiovascular systems and disease.

Pediatrics have not accumulated enough experience in using hematopoietics. Children under 2 years of age are not suitable for patients with hematopoiesis, malignant tumors, epilepsy, thromboembolism, and chronic liver failure. Caution should be used in the use of hematopoietic factors.

Insufficient folic acid or vitamin B12 can reduce the effectiveness of hematopoietic hormones. Severe aluminum overload will also affect the efficacy of hematopoietic.

For non-dialysis sclerosis, the use of hematopoietic factors depends on the individual, and the possibility of accelerating renal failure cannot be ruled out. Serum potassium and phosphate must be monitored regularly. Very few patients with uremia have high potassium levels after the use of hematopoietic, but its causality cannot be determined. If high potassium is found, consideration should be given to discontinuing hematopoietic use until it returns to normal levels.

Heparin 1000-Each bottle contains 1000 IU of Epoetin Beta lyophilized powder, equivalent to 8.3 micrograms of erythropoietin-, each bottle comes with 1 ampoule 1ml water for injection

Heparin 2000-Each bottle contains 2000 International Units (IU) Epoetin Beta lyophilized powder, equivalent to 16.6 micrograms of erythropoietin-, each bottle comes with an ampoule of 1ml water for injection

Heparin 5000-Each bottle contains 5000 IU of Epoetin Bets lyophilized powder, equivalent to 41.5 micrograms of erythropoietin-, each bottle comes with an ampoule of 1ml water for injection

Heparin 10000-Each bottle contains 10,000 International Units (IU) Epoetin Beta lyophilized powder, equal to 83 micrograms of erythropoietin-, each bottle comes with 1 ampoule 1ml water for injection

Heparin 1000, Heparin 2000

10 bottles of lyophilized powder and 5 ampoules of injection solvent per box